Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status
Identifieur interne : 001B60 ( Main/Exploration ); précédent : 001B59; suivant : 001B61Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status
Auteurs : Gülin Öz [États-Unis] ; Diane Hutter [États-Unis] ; Ivan Tká [États-Unis] ; H. Brent Clark [États-Unis] ; Myron D. Gross [États-Unis] ; Hong Jiang [États-Unis, République populaire de Chine] ; Lynn E. Eberly [États-Unis] ; Khalaf O. Bushara [États-Unis] ; Christopher M. Gomez [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-07-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Analysis of Variance, Aspartic Acid (analogs & derivatives), Brain Chemistry, Case-Control Studies, Cerebellum, Female, Functional Laterality, Glial Fibrillary Acidic Protein (cerebrospinal fluid), Humans, Inositol, Isoprostanes (cerebrospinal fluid), MRS, Magnetic Resonance Imaging (methods), Magnetic Resonance Spectroscopy (methods), Male, Middle Aged, Nervous system diseases, Phosphocreatine, Protons (diagnostic use), SCA1, Severity of Illness Index, Spinocerebellar Ataxias (metabolism), Spinocerebellar Ataxias (physiopathology), Spinocerebellar ataxia, Statistics as Topic, ataxia, cerebellum, neurochemical profile.
- MESH :
- chemical , analogs & derivatives : Aspartic Acid.
- chemical , cerebrospinal fluid : Glial Fibrillary Acidic Protein, Isoprostanes.
- chemical , diagnostic use : Protons.
- metabolism : Spinocerebellar Ataxias.
- methods : Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy.
- physiopathology : Spinocerebellar Ataxias.
- Analysis of Variance, Brain Chemistry, Case-Control Studies, Female, Functional Laterality, Humans, Inositol, Male, Middle Aged, Phosphocreatine, Severity of Illness Index, Statistics as Topic.
Abstract
Robust biomarkers of neurodegeneration are critical for testing of neuroprotective therapies. The clinical applicability of such biomarkers requires sufficient sensitivity to detect disease in individuals. Here we tested the sensitivity of high field (4 tesla) proton magnetic resonance spectroscopy (1H MRS) to neurochemical alterations in the cerebellum and brainstem in spinocerebellar ataxia type 1 (SCA1). We measured neurochemical profiles that consisted of 10 to 15 metabolite concentrations in the vermis, cerebellar hemispheres and pons of patients with SCA1 (N = 9) and healthy controls (N = 15). Total NAA (N‐acetylaspartate + N‐acetylaspartylglutamate, tNAA) and glutamate were lower and glutamine, myo‐inositol and total creatine (creatine + phosphocreatine, tCr) were higher in patients relative to controls, consistent with neuronal dysfunction/loss, gliotic activity, and alterations in glutamate–glutamine cycling and energy metabolism. Changes in tNAA, tCr, myo‐inositol, and glutamate levels were discernible in individual spectra and the tNAA/myo‐inositol ratio in the cerebellar hemipheres and pons differentiated the patients from controls with 100% specificity and sensitivity. In addition, tNAA, myo‐inositol, and glutamate levels in the cerebellar hemispheres and the tNAA and myo‐inositol levels in the pons correlated with ataxia scores (Scale for the Assessment and Rating of Ataxia, SARA). Two other biomarkers measured in the cerebrospinal fluid (CSF) of a subset of the volunteers (F2‐isoprostanes asa marker of oxidative stress and glial fibrillary acidic protein (GFAP) as a marker of gliosis) were not different between patients and controls. These data demonstrate that 1H MRS biomarkers can be utilized to noninvasively assess neuronal and glial status in individual ataxia patients. © 2010 Movement Disorder Society
Url:
- https://api.istex.fr/document/0DD77DE275F2F6700E5396735C2BAAFA018D828B/fulltext/pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2916651
DOI: 10.1002/mds.23067
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000255
- to stream Istex, to step Curation: 000255
- to stream Istex, to step Checkpoint: 000839
- to stream Pmc, to step Corpus: 000086
- to stream Pmc, to step Curation: 000086
- to stream Pmc, to step Checkpoint: 000326
- to stream PubMed, to step Corpus: 001875
- to stream PubMed, to step Curation: 001875
- to stream PubMed, to step Checkpoint: 001757
- to stream Ncbi, to step Merge: 002B27
- to stream Ncbi, to step Curation: 002B27
- to stream Ncbi, to step Checkpoint: 002B27
- to stream Main, to step Merge: 001F96
- to stream PascalFrancis, to step Corpus: 000A16
- to stream PascalFrancis, to step Curation: 002303
- to stream PascalFrancis, to step Checkpoint: 000948
- to stream Main, to step Merge: 002535
- to stream Main, to step Curation: 001B60
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status</title><author><name sortKey="Oz, Gulin" sort="Oz, Gulin" uniqKey="Oz G" first="Gülin" last="Öz">Gülin Öz</name></author><author><name sortKey="Hutter, Diane" sort="Hutter, Diane" uniqKey="Hutter D" first="Diane" last="Hutter">Diane Hutter</name></author><author><name sortKey="Tka, Ivan" sort="Tka, Ivan" uniqKey="Tka I" first="Ivan" last="Tká">Ivan Tká</name></author><author><name sortKey="Clark, H Brent" sort="Clark, H Brent" uniqKey="Clark H" first="H. Brent" last="Clark">H. Brent Clark</name></author><author><name sortKey="Gross, Myron D" sort="Gross, Myron D" uniqKey="Gross M" first="Myron D." last="Gross">Myron D. Gross</name></author><author><name sortKey="Jiang, Hong" sort="Jiang, Hong" uniqKey="Jiang H" first="Hong" last="Jiang">Hong Jiang</name></author><author><name sortKey="Eberly, Lynn E" sort="Eberly, Lynn E" uniqKey="Eberly L" first="Lynn E." last="Eberly">Lynn E. Eberly</name></author><author><name sortKey="Bushara, Khalaf O" sort="Bushara, Khalaf O" uniqKey="Bushara K" first="Khalaf O." last="Bushara">Khalaf O. Bushara</name></author><author><name sortKey="Gomez, Christopher M" sort="Gomez, Christopher M" uniqKey="Gomez C" first="Christopher M." last="Gomez">Christopher M. Gomez</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0DD77DE275F2F6700E5396735C2BAAFA018D828B</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23067</idno><idno type="url">https://api.istex.fr/document/0DD77DE275F2F6700E5396735C2BAAFA018D828B/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000255</idno><idno type="wicri:Area/Istex/Curation">000255</idno><idno type="wicri:Area/Istex/Checkpoint">000839</idno><idno type="wicri:doubleKey">0885-3185:2010:Oz G:neurochemical:alterations:in</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2916651</idno><idno type="RBID">PMC:2916651</idno><idno type="wicri:Area/Pmc/Corpus">000086</idno><idno type="wicri:Area/Pmc/Curation">000086</idno><idno type="wicri:Area/Pmc/Checkpoint">000326</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">001875</idno><idno type="wicri:Area/PubMed/Curation">001875</idno><idno type="wicri:Area/PubMed/Checkpoint">001757</idno><idno type="wicri:Area/Ncbi/Merge">002B27</idno><idno type="wicri:Area/Ncbi/Curation">002B27</idno><idno type="wicri:Area/Ncbi/Checkpoint">002B27</idno><idno type="wicri:doubleKey">0885-3185:2010:Oz G:neurochemical:alterations:in</idno><idno type="wicri:Area/Main/Merge">001F96</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:10-0376238</idno><idno type="wicri:Area/PascalFrancis/Corpus">000A16</idno><idno type="wicri:Area/PascalFrancis/Curation">002303</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000948</idno><idno type="wicri:doubleKey">0885-3185:2010:Oz G:neurochemical:alterations:in</idno><idno type="wicri:Area/Main/Merge">002535</idno><idno type="wicri:Area/Main/Curation">001B60</idno><idno type="wicri:Area/Main/Exploration">001B60</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status</title><author><name sortKey="Oz, Gulin" sort="Oz, Gulin" uniqKey="Oz G" first="Gülin" last="Öz">Gülin Öz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for MR Research, Department of Radiology, Medical School, University of Minnesota, Minneapolis, Minnesota</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Hutter, Diane" sort="Hutter, Diane" uniqKey="Hutter D" first="Diane" last="Hutter">Diane Hutter</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for MR Research, Department of Radiology, Medical School, University of Minnesota, Minneapolis, Minnesota</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Tka, Ivan" sort="Tka, Ivan" uniqKey="Tka I" first="Ivan" last="Tká">Ivan Tká</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for MR Research, Department of Radiology, Medical School, University of Minnesota, Minneapolis, Minnesota</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Clark, H Brent" sort="Clark, H Brent" uniqKey="Clark H" first="H. Brent" last="Clark">H. Brent Clark</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Laboratory Medicine and Pathology, Medical School, University of Minnesota, Minneapolis, Minnesota</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Gross, Myron D" sort="Gross, Myron D" uniqKey="Gross M" first="Myron D." last="Gross">Myron D. Gross</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Laboratory Medicine and Pathology, Medical School, University of Minnesota, Minneapolis, Minnesota</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Jiang, Hong" sort="Jiang, Hong" uniqKey="Jiang H" first="Hong" last="Jiang">Hong Jiang</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Chicago, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>Current Address: Department of Neurology, Xiangya Hospital Neurodegenerative Disorders Research Center, Central South University, Changsha, Hunan</wicri:regionArea><wicri:noRegion>Hunan</wicri:noRegion></affiliation></author><author><name sortKey="Eberly, Lynn E" sort="Eberly, Lynn E" uniqKey="Eberly L" first="Lynn E." last="Eberly">Lynn E. Eberly</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Bushara, Khalaf O" sort="Bushara, Khalaf O" uniqKey="Bushara K" first="Khalaf O." last="Bushara">Khalaf O. Bushara</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Medical School, University of Minnesota, Minneapolis, Minnesota</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Gomez, Christopher M" sort="Gomez, Christopher M" uniqKey="Gomez C" first="Christopher M." last="Gomez">Christopher M. Gomez</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Chicago, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-07-15">2010-07-15</date><biblScope unit="vol">25</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1253">1253</biblScope><biblScope unit="page" to="1261">1261</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">0DD77DE275F2F6700E5396735C2BAAFA018D828B</idno><idno type="DOI">10.1002/mds.23067</idno><idno type="ArticleID">MDS23067</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analysis of Variance</term><term>Aspartic Acid (analogs & derivatives)</term><term>Brain Chemistry</term><term>Case-Control Studies</term><term>Cerebellum</term><term>Female</term><term>Functional Laterality</term><term>Glial Fibrillary Acidic Protein (cerebrospinal fluid)</term><term>Humans</term><term>Inositol</term><term>Isoprostanes (cerebrospinal fluid)</term><term>MRS</term><term>Magnetic Resonance Imaging (methods)</term><term>Magnetic Resonance Spectroscopy (methods)</term><term>Male</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Phosphocreatine</term><term>Protons (diagnostic use)</term><term>SCA1</term><term>Severity of Illness Index</term><term>Spinocerebellar Ataxias (metabolism)</term><term>Spinocerebellar Ataxias (physiopathology)</term><term>Spinocerebellar ataxia</term><term>Statistics as Topic</term><term>ataxia</term><term>cerebellum</term><term>neurochemical profile</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Aspartic Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="cerebrospinal fluid" xml:lang="en"><term>Glial Fibrillary Acidic Protein</term><term>Isoprostanes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Protons</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Spinocerebellar Ataxias</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Magnetic Resonance Imaging</term><term>Magnetic Resonance Spectroscopy</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Spinocerebellar Ataxias</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term><term>Brain Chemistry</term><term>Case-Control Studies</term><term>Female</term><term>Functional Laterality</term><term>Humans</term><term>Inositol</term><term>Male</term><term>Middle Aged</term><term>Phosphocreatine</term><term>Severity of Illness Index</term><term>Statistics as Topic</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Ataxie spinocérébelleuse</term><term>Cervelet</term><term>Pathologie du système nerveux</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Robust biomarkers of neurodegeneration are critical for testing of neuroprotective therapies. The clinical applicability of such biomarkers requires sufficient sensitivity to detect disease in individuals. Here we tested the sensitivity of high field (4 tesla) proton magnetic resonance spectroscopy (1H MRS) to neurochemical alterations in the cerebellum and brainstem in spinocerebellar ataxia type 1 (SCA1). We measured neurochemical profiles that consisted of 10 to 15 metabolite concentrations in the vermis, cerebellar hemispheres and pons of patients with SCA1 (N = 9) and healthy controls (N = 15). Total NAA (N‐acetylaspartate + N‐acetylaspartylglutamate, tNAA) and glutamate were lower and glutamine, myo‐inositol and total creatine (creatine + phosphocreatine, tCr) were higher in patients relative to controls, consistent with neuronal dysfunction/loss, gliotic activity, and alterations in glutamate–glutamine cycling and energy metabolism. Changes in tNAA, tCr, myo‐inositol, and glutamate levels were discernible in individual spectra and the tNAA/myo‐inositol ratio in the cerebellar hemipheres and pons differentiated the patients from controls with 100% specificity and sensitivity. In addition, tNAA, myo‐inositol, and glutamate levels in the cerebellar hemispheres and the tNAA and myo‐inositol levels in the pons correlated with ataxia scores (Scale for the Assessment and Rating of Ataxia, SARA). Two other biomarkers measured in the cerebrospinal fluid (CSF) of a subset of the volunteers (F2‐isoprostanes asa marker of oxidative stress and glial fibrillary acidic protein (GFAP) as a marker of gliosis) were not different between patients and controls. These data demonstrate that 1H MRS biomarkers can be utilized to noninvasively assess neuronal and glial status in individual ataxia patients. © 2010 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>République populaire de Chine</li><li>États-Unis</li></country><region><li>Illinois</li><li>Minnesota</li></region></list><tree><country name="États-Unis"><region name="Minnesota"><name sortKey="Oz, Gulin" sort="Oz, Gulin" uniqKey="Oz G" first="Gülin" last="Öz">Gülin Öz</name></region><name sortKey="Bushara, Khalaf O" sort="Bushara, Khalaf O" uniqKey="Bushara K" first="Khalaf O." last="Bushara">Khalaf O. Bushara</name><name sortKey="Clark, H Brent" sort="Clark, H Brent" uniqKey="Clark H" first="H. Brent" last="Clark">H. Brent Clark</name><name sortKey="Eberly, Lynn E" sort="Eberly, Lynn E" uniqKey="Eberly L" first="Lynn E." last="Eberly">Lynn E. Eberly</name><name sortKey="Gomez, Christopher M" sort="Gomez, Christopher M" uniqKey="Gomez C" first="Christopher M." last="Gomez">Christopher M. Gomez</name><name sortKey="Gross, Myron D" sort="Gross, Myron D" uniqKey="Gross M" first="Myron D." last="Gross">Myron D. Gross</name><name sortKey="Hutter, Diane" sort="Hutter, Diane" uniqKey="Hutter D" first="Diane" last="Hutter">Diane Hutter</name><name sortKey="Jiang, Hong" sort="Jiang, Hong" uniqKey="Jiang H" first="Hong" last="Jiang">Hong Jiang</name><name sortKey="Tka, Ivan" sort="Tka, Ivan" uniqKey="Tka I" first="Ivan" last="Tká">Ivan Tká</name></country><country name="République populaire de Chine"><noRegion><name sortKey="Jiang, Hong" sort="Jiang, Hong" uniqKey="Jiang H" first="Hong" last="Jiang">Hong Jiang</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B60 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001B60 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:0DD77DE275F2F6700E5396735C2BAAFA018D828B
|texte= Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status
}}
| This area was generated with Dilib version V0.6.23. |  |